The effect of colchicine on cancer risk in patients with immune-mediated inflammatory diseases: a time-dependent study based on the Taiwan’s National Health Insurance Research Database

Table 3 Incidence and adjusted hazard ratio of colorectal cancer stratified by duration of colchicine therapy in patients with the immune-mediated inflammatory diseases in the propensity score-matched cohort

Medication exposed	N	Event	Person-year	Rate	Adjusted HR (95% CI)^b
Colorectal cancer
Colchicine^a
Non-colchicine	16,026	170	123,693	1.37	1.00
> 15 ≤ 20 days	8099	18	61,764	1.10	0.81 (0.61, 1.08)
21–100 days	4036	13	30,949	0.80	0.58 (0.45, 0.99)*
> 100 days	3891	8	30,096	0.23	0.17 (0.15, 0.66)**

^aThe cumulative use day are partitioned in to 3 segments by median, and third quartile
Adjusted HR^b: multivariable analysis including age, sex, comorbidities and medications
^*p < 0.05, **p < 0.01

ISSN: 2047-783X